Although prostate cancer can be stabilized or regressed by androgen deprivation therapy, reactivation of AR by overexpression, point mutation, alternative splicing and other ligand-independent manners ultimately lead to incurable castration-resistant prostate cancer (CRPC) [3]. This evidence concerns the gene AR and prostate carcinoma.